NO995132L - Fremgangsmåte for reduksjon av fibrinogen - Google Patents

Fremgangsmåte for reduksjon av fibrinogen

Info

Publication number
NO995132L
NO995132L NO995132A NO995132A NO995132L NO 995132 L NO995132 L NO 995132L NO 995132 A NO995132 A NO 995132A NO 995132 A NO995132 A NO 995132A NO 995132 L NO995132 L NO 995132L
Authority
NO
Norway
Prior art keywords
reducing fibrinogen
fibrinogen
reducing
arylbenzoäbüthiophene
aroyl
Prior art date
Application number
NO995132A
Other languages
English (en)
Other versions
NO995132D0 (no
Inventor
Pamela W Anderson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO995132D0 publication Critical patent/NO995132D0/no
Publication of NO995132L publication Critical patent/NO995132L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO995132A 1997-04-22 1999-10-21 Fremgangsmåte for reduksjon av fibrinogen NO995132L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4459197P 1997-04-22 1997-04-22
PCT/US1998/007862 WO1998047365A1 (en) 1997-04-22 1998-04-20 Methods for reducing fibrinogen

Publications (2)

Publication Number Publication Date
NO995132D0 NO995132D0 (no) 1999-10-21
NO995132L true NO995132L (no) 1999-10-21

Family

ID=21933208

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995132A NO995132L (no) 1997-04-22 1999-10-21 Fremgangsmåte for reduksjon av fibrinogen

Country Status (23)

Country Link
US (1) US6025373A (no)
EP (1) EP0878195B1 (no)
JP (1) JP2001524101A (no)
KR (1) KR20010012084A (no)
CN (1) CN1254255A (no)
AT (1) ATE219364T1 (no)
AU (1) AU741720B2 (no)
BR (1) BR9809286A (no)
CA (1) CA2287196A1 (no)
DE (1) DE69806098T2 (no)
DK (1) DK0878195T3 (no)
EA (1) EA002237B1 (no)
ES (1) ES2178111T3 (no)
HU (1) HUP0002727A3 (no)
ID (1) ID22910A (no)
IL (1) IL132504A0 (no)
NO (1) NO995132L (no)
NZ (1) NZ500389A (no)
PL (1) PL336638A1 (no)
PT (1) PT878195E (no)
TR (1) TR199902605T2 (no)
WO (1) WO1998047365A1 (no)
ZA (1) ZA983298B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103740A (en) * 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6353003B1 (en) * 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
ATE172623T1 (de) * 1991-12-17 1998-11-15 Dynamics Imaging Inc Verfahren und vorrichtung zur diagnose von lebenden organismen
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
CZ253694A3 (en) * 1993-10-15 1995-05-17 Lilly Co Eli Pharmaceutical preparation for treating resistant neoplasms
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
CN1173819A (zh) * 1995-02-06 1998-02-18 伊莱利利公司 抑制il-6作用的方法
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1

Also Published As

Publication number Publication date
ID22910A (id) 1999-12-16
DK0878195T3 (da) 2002-07-15
AU7250398A (en) 1998-11-13
HUP0002727A2 (hu) 2001-08-28
BR9809286A (pt) 2000-07-04
TR199902605T2 (xx) 2000-02-21
NO995132D0 (no) 1999-10-21
DE69806098T2 (de) 2003-01-02
EA199900959A1 (ru) 2000-06-26
NZ500389A (en) 2001-07-27
JP2001524101A (ja) 2001-11-27
ZA983298B (en) 1999-10-20
MX9909548A (es) 2003-02-27
EP0878195A1 (en) 1998-11-18
ES2178111T3 (es) 2002-12-16
PL336638A1 (en) 2000-07-03
KR20010012084A (ko) 2001-02-15
CN1254255A (zh) 2000-05-24
WO1998047365A1 (en) 1998-10-29
ATE219364T1 (de) 2002-07-15
IL132504A0 (en) 2001-03-19
PT878195E (pt) 2002-09-30
HUP0002727A3 (en) 2001-09-28
EP0878195B1 (en) 2002-06-19
DE69806098D1 (de) 2002-07-25
CA2287196A1 (en) 1998-10-29
AU741720B2 (en) 2001-12-06
US6025373A (en) 2000-02-15
EA002237B1 (ru) 2002-02-28

Similar Documents

Publication Publication Date Title
AU696851B2 (en) Method of treating hyperproliferative vascular disease
CO4230019A1 (es) Antagonistas de neuroquinina diazabiciclica
HN1998000036A (es) Compuesto de pirazina
ES2093361T3 (es) Tratamiento de enfermedades neurodegenerativas.
FI945703A0 (fi) 3,4,4-trisybstituoitujen piperidinyyli-N-alkyylikarboksylaattien ja välituotteiden valmistus
DE69516866D1 (de) Stereochemische wortmanninderivate
FI970032L (fi) Terapeuttisia yhdisteitä
FI953899A0 (fi) Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi
FI954007A0 (fi) Substituoitujen 4-fenyyli-6-amino-nikotiinihappojohdannaisten käyttö lääkeaineena
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
ES2179254T3 (es) 1-poliarilpirazoles plaguicidas.
IT1277446B1 (it) Macchina per la costruzione di binari
DE68916850D1 (de) Antikoagulierende Peptid-Alkohole.
DE69505134D1 (de) Herstellung von halogeniersen verbindungen
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
NO924361L (no) Formazan parasittiske midler
LV11463A (lv) Aizvietotu 4,6-diamino-5-cianpirimidinu iegusanas panemiens
DE69410957D1 (de) Herstellung von Thioetherverbindungen
FI932196A7 (fi) Menetelmä fibrinogeenin määrittämiseksi
DK0520372T3 (da) Inositol-phosphat-analoger som calciumantagonistiske stoffer
ATE176477T1 (de) Neue phospholipidderivate
FI880868A0 (fi) Välituotteina käyttökelpoisia tetratsoliyhdisteitä

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application